184 related articles for article (PubMed ID: 24887664)
41. Risk factors and clinicopathological study of prognostic factors in the peritoneal mesothelioma.
Tudor EC; Chua TC; Liauw W; Morris DL
Am Surg; 2010 Apr; 76(4):400-5. PubMed ID: 20420251
[TBL] [Abstract][Full Text] [Related]
42. Toxicity and quality of life after cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy.
Tuttle TM; Zhang Y; Greeno E; Knutsen A
Ann Surg Oncol; 2006 Dec; 13(12):1627-32. PubMed ID: 17013686
[TBL] [Abstract][Full Text] [Related]
43. Clinico-pathological outcomes after total parietal peritonectomy, cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in advanced serous papillary peritoneal carcinoma submitted to neoadjuvant systemic chemotherapy- largest single institute experience.
Deraco M; Sinukumar S; Salcedo-Hernández RA; Rajendra VJ; Baratti D; Guaglio M; Nizri E; Kusamura S
Eur J Surg Oncol; 2019 Nov; 45(11):2103-2108. PubMed ID: 31230982
[TBL] [Abstract][Full Text] [Related]
44. [Treatment of the peritoneal carcinomatosis by cytoreductive surgery and intraperitoneal hyperthermic chemotherapy (IHPC): postoperative morbidity and mortality and short-term follow-up].
Minicozzi A; Borzellino G; Momo EN; Segattini C; Pitoni F; Steccanella F; De Manzoni G
Ann Ital Chir; 2008; 79(4):231-9. PubMed ID: 19093624
[TBL] [Abstract][Full Text] [Related]
45. [Malignant peritoneal mesothelioma. Our experienced with triple combined therapy: cytoreduction, intraperitoneal perioperative chemotherapy and hyperthermia].
Gómez Portilla A; Cendoya I; Muriel J; Olabarria I; Guede N; Moraza N; Fernández E; Martínez de Lecea C; Magrach L; Martín E; Romero E; Aguado I; Valdovinos M; Larrabide I
Cir Esp; 2007 Feb; 81(2):82-6. PubMed ID: 17306123
[TBL] [Abstract][Full Text] [Related]
46. The role of perioperative systemic chemotherapy in diffuse malignant peritoneal mesothelioma patients treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.
Deraco M; Baratti D; Hutanu I; Bertuli R; Kusamura S
Ann Surg Oncol; 2013 Apr; 20(4):1093-100. PubMed ID: 23456386
[TBL] [Abstract][Full Text] [Related]
47. The Role of Ki-67 and Pre-cytoreduction Parameters in Selecting Diffuse Malignant Peritoneal Mesothelioma (DMPM) Patients for Cytoreductive Surgery (CRS) and Hyperthermic Intraperitoneal Chemotherapy (HIPEC).
Kusamura S; Torres Mesa PA; Cabras A; Baratti D; Deraco M
Ann Surg Oncol; 2016 May; 23(5):1468-73. PubMed ID: 26572754
[TBL] [Abstract][Full Text] [Related]
48. Comprehensive management of diffuse malignant peritoneal mesothelioma.
Sugarbaker PH; Yan TD; Stuart OA; Yoo D
Eur J Surg Oncol; 2006 Aug; 32(6):686-91. PubMed ID: 16621431
[TBL] [Abstract][Full Text] [Related]
49. Extensive surgical cytoreduction and intraoperative hyperthermic intraperitoneal chemotherapy in patients with pseudomyxoma peritonei.
Witkamp AJ; de Bree E; Kaag MM; van Slooten GW; van Coevorden F; Zoetmulder FA
Br J Surg; 2001 Mar; 88(3):458-63. PubMed ID: 11260116
[TBL] [Abstract][Full Text] [Related]
50. Is Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy Justified for Biphasic Variants of Peritoneal Mesothelioma? Outcomes from the Peritoneal Surface Oncology Group International Registry.
Votanopoulos KI; Sugarbaker P; Deraco M; Morris D; Glehen O; Elias D; De Simone M; Robella M; Heyd B; Kusamura S; Baratti D; Chouliaras K; Russell G; Shen P; Levine EA;
Ann Surg Oncol; 2018 Mar; 25(3):667-673. PubMed ID: 29260418
[TBL] [Abstract][Full Text] [Related]
51. Multicystic and diffuse malignant peritoneal mesothelioma in children.
Vermersch S; Arnaud A; Orbach D; Andre N; Berger C; Kepenekian V; Brigand C; Fresneau B; Poli-Merol ML; Habougit C; Varlet F; Scalabre A
Pediatr Blood Cancer; 2020 Jun; 67(6):e28286. PubMed ID: 32277799
[TBL] [Abstract][Full Text] [Related]
52. Iterative procedures combining cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for isolated peritoneal recurrence.
Vaira M; Robella M; Mellano A; Sottile A; De Simone M
Int J Hyperthermia; 2014 Dec; 30(8):565-9. PubMed ID: 25430988
[TBL] [Abstract][Full Text] [Related]
53. Oxaliplatin versus Mitomycin C for HIPEC in colorectal cancer peritoneal carcinomatosis.
Leung V; Huo YR; Liauw W; Morris DL
Eur J Surg Oncol; 2017 Jan; 43(1):144-149. PubMed ID: 27780675
[TBL] [Abstract][Full Text] [Related]
54. Clinical and surgical outcomes of patients with peritoneal mesothelioma discussed at a monthly national multidisciplinary team video-conference meeting.
Brandl A; Westbrook S; Nunn S; Arbuthnot-Smith E; Mulsow J; Youssef H; Carr N; Tzivanakis A; Dayal S; Mohamed F; Moran BJ; Cecil T
BJS Open; 2020 Apr; 4(2):260-267. PubMed ID: 32003132
[TBL] [Abstract][Full Text] [Related]
55. The effects of adjuvant experimental radioimmunotherapy and hyperthermic intraperitoneal chemotherapy on intestinal and abdominal healing after cytoreductive surgery for peritoneal carcinomatosis in the rat.
Aarts F; Bleichrodt RP; de Man B; Lomme R; Boerman OC; Hendriks T
Ann Surg Oncol; 2008 Nov; 15(11):3299-307. PubMed ID: 18712445
[TBL] [Abstract][Full Text] [Related]
56. Does early post-operative intraperitoneal chemotherapy (EPIC) for patients treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) make a difference?
Tan GH; Ong WS; Chia CS; Tham CK; Soo KC; Teo MC
Int J Hyperthermia; 2016 May; 32(3):281-8. PubMed ID: 26862667
[TBL] [Abstract][Full Text] [Related]
57. A comparison between radioimmunotherapy and hyperthermic intraperitoneal chemotherapy for the treatment of peritoneal carcinomatosis of colonic origin in rats.
Aarts F; Hendriks T; Boerman OC; Koppe MJ; Oyen WJ; Bleichrodt RP
Ann Surg Oncol; 2007 Nov; 14(11):3274-82. PubMed ID: 17653591
[TBL] [Abstract][Full Text] [Related]
58. Institutional learning curve of cytoreductive surgery and hyperthermic intraperitoneal chemoperfusion for peritoneal malignancies.
Polanco PM; Ding Y; Knox JM; Ramalingam L; Jones H; Hogg ME; Zureikat AH; Holtzman MP; Pingpank J; Ahrendt S; Zeh HJ; Bartlett DL; Choudry HA
Ann Surg Oncol; 2015 May; 22(5):1673-9. PubMed ID: 25377640
[TBL] [Abstract][Full Text] [Related]
59. Colorectal peritoneal carcinomatosis treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: the experience of a tertiary Asian center.
Teo MC; Ching Tan GH; Lim C; Chia CS; Tham CK; Soo KC
Asian J Surg; 2015 Apr; 38(2):65-73. PubMed ID: 25059814
[TBL] [Abstract][Full Text] [Related]
60. Malignant Peritoneal Mesothelioma: National Practice Patterns, Outcomes, and Predictors of Survival.
Verma V; Sleightholm RL; Rusthoven CG; Koshy M; Sher DJ; Grover S; Simone CB
Ann Surg Oncol; 2018 Jul; 25(7):2018-2026. PubMed ID: 29721724
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
